Mark Schofield is a former college quarterback and attorney covering the NFL and F1. Perhaps the marquee event of any Winter Olympics, women’s individual figure skating got underway Tuesday and Italy.

Editor's note: Alysa Liu won Olympic gold in women's figure skating. MILAN — The night started with promise and hope for the U.S. women's figure skating team. The trio of "Blade Angels" — close ...

Recursion Pharmaceuticals RXRX, a TechBio company that decodes biology and chemistry to industrialize drug discovery, is expected to report fourth-quarter 2025 results soon. The Zacks Consensus ...

MILAN — Figure skating is more than halfway done at the 2026 Winter Olympics, with the pairs next to take the ice at the Milan Ice Skating Arena. Riku Miura and Ryuichi Kihara of Japan react after ...

MILAN — It’s reckless and exhilarating, daring and unnecessary, thrilling and chaotic all at once. The mid-routine backflip is one of skating’s most controversial moves, and Ilia Malinin — for the ...

Ilia Malinin hadn't finished outside of first place in any figure skating events he's competed in for multiple years. And while it wasn't the most important one he'll have at the 2026 Winter Olympics, ...

Starbucks is revamping its loyalty program and one of the new twists is that you can keep your rewards stars from expiring. The revamped program will launch on March 10 with three free membership ...

Recursive language models (RLMs) are an inference technique developed by researchers at MIT CSAIL that treat long prompts as an external environment to the model. Instead of forcing the entire prompt ...

In response to fan research that shows a clear desire to see the best golfers competing together more often – as well as timely inquiries from players not currently competing on the PGA TOUR and ...

Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...

Recursion Pharmaceuticals Inc (NASDAQ: RXRX) shares moved higher Wednesday after JPMorgan upgraded the stock to Overweight from Neutral and lifted its price target to $11 from $10. What Happened: ...